Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 35A Convent Drive, Room GF103, NIDCD/NIH, Bethesda, MD, USA.
Division of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
BMC Med Genet. 2019 Jul 2;20(1):118. doi: 10.1186/s12881-019-0853-4.
Recessive mutations of coding regions and splice sites of the SLC26A4 gene cause hearing loss with enlargement of the vestibular aqueduct (EVA). Some patients also have a thyroid iodination defect that can lead to multinodular goiter as part of Pendred syndrome. A haplotype of variants upstream of SLC26A4, called CEVA, acts as a pathogenic recessive allele in trans to mutations affecting the coding regions or splice sites of SLC26A4. Our first hypothesis is that CEVA, acting as a pathogenic recessive allele, is correlated with a less severe phenotype than mutations affecting the coding regions and splice sites of SLC26A4. Our second hypothesis is that CEVA acts as a modifier of the phenotype in patients with EVA caused by mutations affecting the coding regions or splice sites of both alleles of SLC26A4 or EVA caused by other factors.
This was a prospective cohort study of 114 individuals and 202 ears with EVA. To test our first hypothesis, we compared the thyroid and auditory phenotypes of subjects with mutations affecting coding regions of both alleles of SLC26A4 with those of subjects carrying CEVA in trans to mutations affecting the coding regions. To test our second hypothesis, we compared the phenotypes associated with the presence versus absence of CEVA among subjects with no coding region mutations, as well as among subjects with mutations affecting coding regions of both alleles.
Subjects carrying CEVA in trans to a mutation of SLC26A4 have a normal thyroid phenotype and less severe hearing loss in comparison to individuals with mutations affecting coding regions of both alleles of SLC26A4. In subjects with no mutant alleles of SLC26A4, hearing loss was more severe in subjects who carry the CEVA haplotype in comparison to non-carriers. There was no correlation of CEVA with the phenotype of subjects with mutations affecting coding regions of both alleles.
CEVA, acting as a likely pathogenic recessive allele, is associated with a less severe phenotype than alleles with a mutation affecting the coding regions or splice sites of SLC26A4. CEVA may act as a genetic modifier in patients with EVA caused by other factors.
SLC26A4 基因编码区和剪接位点的隐性突变可导致前庭导水管扩大(EVA)伴听力损失。部分患者还存在甲状腺碘化缺陷,可导致多结节性甲状腺肿,这是 Pendred 综合征的一部分。SLC26A4 上游的一种称为 CEVA 的变异单体型,作为一个致病性的隐性等位基因,在顺式作用于影响 SLC26A4 编码区或剪接位点的突变。我们的第一个假设是,CEVA 作为一个致病性隐性等位基因,与影响 SLC26A4 编码区和剪接位点的突变相比,表型较轻。我们的第二个假设是,CEVA 作为一种修饰基因,可改变由 SLC26A4 两个等位基因突变或其他因素导致的 EVA 患者的表型。
这是一项前瞻性队列研究,共纳入 114 名个体和 202 只 EVA 耳。为了检验我们的第一个假设,我们比较了同时携带 SLC26A4 两个等位基因突变影响编码区的患者和携带影响编码区突变的 CEVA 患者的甲状腺和听觉表型。为了检验我们的第二个假设,我们比较了无编码区突变患者以及同时携带 SLC26A4 两个等位基因突变影响编码区患者中 CEVA 存在与缺失的表型差异。
携带 SLC26A4 突变的 CEVA 患者甲状腺表型正常,与同时携带 SLC26A4 两个等位基因突变影响编码区的患者相比,听力损失程度较轻。在无 SLC26A4 突变等位基因的患者中,携带 CEVA 单体型的患者与非携带者相比,听力损失更严重。CEVA 与影响 SLC26A4 两个等位基因突变的患者表型之间无相关性。
CEVA 作为一个可能的致病性隐性等位基因,与影响 SLC26A4 编码区或剪接位点的突变相比,表型较轻。CEVA 可能是由其他因素导致的 EVA 患者的遗传修饰基因。